Risk factors
Dogwood Therapeutics (DWTX) risk factors
Item 1A of every Dogwood Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
60 risks, 6 new, 12 dropped, 16 reworded since the prior year. Dogwood Therapeutics shifted its active development pipeline from IMC-1 and IMC-2 to SP16 alongside Halneuron.
Filed Mar 18, 2026 - FY2024 10-K risk factors
66 risks. Development-stage biotech facing ongoing net losses, significant accumulated deficit, and heavy reliance on capital raises to fund trials.
Filed Mar 31, 2025